Uses of Latyzi

Latyz drug containing the active ingredient Lamivudin is indicated in the treatment of chronic hepatitis B in patients with evidence of hepatitis B virus replication... Let's learn about the uses and notes when using Latyz through this article. write below.

“What disease does Latyz treat?”. Latyz contains the active ingredient Lamivudine and is available in the form of film-coated tablets.
Lamivudine belongs to the group of antiviral drugs with high activity against hepatitis B virus in laboratory animals and test cell lines. After administration, Lamivudine is converted to the active form triphosphate (TP). Lamivudine TP acts as a substrate for the HBV viral polymerase, making further formation of viral DNA impossible due to the incorporation of Lamivudine into the strand and resulting chain termination.
Latyz is indicated in the following cases:
Treatment of chronic hepatitis B in patients with evidence of viral replication; Combination with Zidovudine in the treatment of HIV in children over 3 months of age and adults.

Dosage of Latyz drug is prescribed by the treating doctor based on the patient's pathology and tolerability. Some recommendations on the dosage of Latyz are as follows:
Treatment of chronic hepatitis B: Adults use a dose of 100mg/day, children from 12 years old use a dose of 3mg/kg/day, up to a maximum of 100mg/day. Dosage in patients with renal impairment should be adjusted depending on creatinine clearance; Combination with Zidovudine in HIV treatment: Adults take a dose of 150mg/time x 2 times/day in combination with Zidovudine at a dose of 600mg/day divided into 2-3 oral doses. Children use a dose of 4mg/kg/time x 2 times/day, up to 300mg/day, combined with Zidovudine at a dose of 360-720mg/day divided into several oral doses. Dosage in patients with renal impairment should be adjusted depending on creatinine clearance. Hepatic Impairment: The pharmacokinetics of Lamivudine are not affected in patients with hepatic impairment, so no dose adjustment is required in these patients.

Latyz may cause some side effects as follows:
Common: Irritability, fatigue, headache, respiratory infection, upset stomach and abdominal pain, nausea and vomiting, diarrhea; Rare: Fatty liver, hepatomegaly, lactic acidosis, pancreatitis, appearance of mutant virus with reduced sensitivity to the drug, decreased response to treatment. Patients need to stop using Latyz and notify the treating doctor in case of any unwanted effects.

Contraindicated to use Latyz in patients with hypersensitivity to Lamivudine or any of its ingredients.
Use caution when using Latyz in the following cases:
Use caution when using Latyz in patients with impaired renal function. The use of drugs in these subjects should be prescribed by the treating doctor and the patient should be carefully monitored; Stop using Latyz when there are symptoms of pancreatitis, the patient needs to be periodically clinical monitoring and liver function tests; In case of discontinuation of the drug, the patient should be periodically monitored to detect evidence if hepatitis recurs. Before treating hepatitis B with Latyz, it is necessary to make sure that the patient is not co-infected with HIV, because low-dose Lamivudine in the treatment of hepatitis B increases the risk of Lamivudin-resistant strains of HIV; Before treatment with Latyz, the patient should be informed that Lamivudin has not been cured of HIV infection, the patient continues to carry the HIV virus (including the risk of opportunistic infections). Therefore, during treatment with Latyz, patients need to be monitored and taken continuously and Latyz does not reduce the risk of HIV transmission; For pregnant women: Lamivudine does not prevent mother-to-child transmission of hepatitis B virus. Therefore, caution should be exercised when Latyz is used in pregnant women (weighing the benefits and risks of treatment). Use only Latyz in combination with zidovudine in pregnant women with hepatitis B during the third trimester of pregnancy to reduce HBV development. Do not use the drug in the first 3 months and the second 3 months of pregnancy because of the risk of birth defects for the fetus; For lactating women: Lamivudine is excreted in breast milk, so HIV-infected mothers who are taking Latyz should not breastfeed their babies.

Latyz drug has a synergistic effect with antidiarrheal drugs and anti-HIV virus (Maravioc, Enfuvirtit). HIV protease inhibitors (Fosamprenavir, Amprenavir, Ritonavir, Nelfinavir, Tipranavir) have a synergistic effect with Lamivudin, specifically as follows: Peak plasma concentrations of Lamivudin are increased when co-administered with Nelfinavir; There is no pharmacokinetic interaction when Lamivudine is co-administered with ritonavir, lopinavir... Lamivudin and non-nucleoside reverse transcriptase inhibitors (Enfavirens, Delavirdin, Nevirapin) have a synergistic effect on HIV-1. Concentrations in HIV-1. Zidovudine plasma increased by 13% when co-administered with Lamivudine. Lamivudin plasma concentrations were reduced by 24% when co-administered with tenofovir. Concomitant use of Latyz and Interferon alpha increases hepatotoxicity and may cause fatal liver failure. Lamivudine AUC was increased by 43% when co-administered with Trimethoprim/Sulphamethoxazole, but no dose adjustment was required. Latyz drug containing the active ingredient Lamivudin is indicated in the treatment of chronic hepatitis B in patients with evidence of hepatitis B virus replication. To ensure effective treatment and avoid unwanted side effects, patients need to Follow the instructions of your doctor or pharmacist exactly.
Follow Vinmec International General Hospital website to get more health, nutrition and beauty information to protect the health of yourself and your loved ones in your family.